Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

Core Viewpoint - Johnson & Johnson (JNJ) is valued at $565 billion and benefits from a diversified business model that enhances its resilience during economic cycles [1][8]. Business Model and Product Range - The company operates through pharmaceuticals and medical devices divisions, covering areas such as neuroscience, cardiovascular health, immunology, oncology, and infectious diseases [2][8]. - JNJ also offers products in orthopedics, surgery, interventional solutions, and vision markets [2]. Stock Performance and Technical Indicators - JNJ's stock has seen significant appreciation, with a 22.94% increase since a "Buy" signal was issued on November 11 [3]. - The stock recently reached an all-time high of $240 on February 6 and is currently trading at $239.41, with a 50-day moving average of $213.25 [6][9]. - JNJ has a Weighted Alpha of +65.98 and has gained 55.99% over the past 52 weeks [9]. - The stock maintains a 100% "Buy" technical opinion from Barchart, although analyst sentiment is mixed regarding its valuation [8][9]. Financial Metrics - JNJ has a trailing price-earnings ratio of 21.71x and a dividend yield of 2.18% [10]. - Revenue is projected to grow by 6.78% this year and an additional 5.15% next year, while earnings are estimated to increase by 6.90% this year and 8.76% next year [10].